Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Disease × Cisplatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 44 Squamous Cell Carcinoma of Head and Neck 20 Lung Neoplasms 18 Head and Neck Neoplasms 17 Neoplasms 16 Urinary Bladder Neoplasms 12 Stomach Neoplasms 12 Esophageal Neoplasms 11 Pancreatic Neoplasms 10 Ovarian Neoplasms 10 Colorectal Neoplasms 10 Uterine Cervical Neoplasms 9 Small Cell Lung Carcinoma 9 Biliary Tract Neoplasms 9 Carcinoma, Transitional Cell 8 Triple Negative Breast Neoplasms 7 Neoplasm Metastasis 7 Melanoma 7 Breast Neoplasms 7 Mesothelioma, Malignant 6 Carcinoma, Squamous Cell 6 Recurrence 5 Oropharyngeal Neoplasms 5 Nasopharyngeal Carcinoma 5 Esophageal Squamous Cell Carcinoma 5 Nasopharyngeal Neoplasms 4 Mouth Neoplasms 4 Cholangiocarcinoma 4 Carcinoma, Small Cell 4 Adenocarcinoma Of Esophagus 4

Interventions

carfilzomib 2 Dexamethasone 2 Cyclophosphamide 2 tivozanib 1 tislelizumab 1 pembrolizumab 1 neratinib 1 Nivolumab 1 Interleukin-15 1 Gemcitabine 1 Erlotinib Hydrochloride 1 Cisplatin 1 Capecitabine 1 Calcium Dobesilate 1 Bevacizumab 1 Albumin-Bound Paclitaxel 1 3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01730222 2017-09-01

PACT-19

IRCCS San Raffaele

Phase 1/2 Completed

Gastrointestinal

Disease, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡